Abstract: SA-PO120
Renal Safety of FLOT Regimen for Gastroesophageal Cancer: Time for Break Boundaries?
Session Information
- Onconephrology: Clinical and Research Advances - II
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1600 Onconephrology
Authors
- Trevisani, Francesco, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Floris, Matteo, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
- Cinque, Alessandra, BIOREK s.r.l., Milan, Lombardia, Italy
- Minnei, Roberto, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
- Pani, Antonello, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
- Angioi, Andrea, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
- Scartozzi, Mario, Universita degli Studi di Cagliari, Cagliari, Sardegna, Italy
- Puzzoni, Marco, Universita degli Studi di Cagliari, Cagliari, Sardegna, Italy
- Amodeo, Jaime, Universita degli Studi di Cagliari, Cagliari, Sardegna, Italy
- Liscia, Nicole, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Mazza, Elena A., IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Cascinu, Stefano, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
Background
Currently, peri-operative docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) chemotherapy (CTx) is the gold standard treatment for pts with locally advanced gastric cancer (LAGC), who undergo peri-operative CTx and surgery. The nephrotoxicity of both docetaxel and oxaliplatin may limit the use in CKD pts. Since limited evidence is available, we explored FLOT effects on renal function in our LAGC population.
Methods
Retrospective data on patient with LAGC in 3 tertiary hospital between jan/2018 to jan/2022 have been analyzed. Pts have been treated with FLOT, administered every 2 weeks, 4 times before surgery. SCr, Hb, and CKD-EPI eGFR were detected before each cycle. AKI and CKD onset/prevalence were determined according to K-DIGO criteria.
Results
A consecutive cohort of 73 pts was enrolled. Baseline CKD was present in 16 pts (21.9%). Median eGFR was 106.2 ml/min. ANOVA showed no significant differences between cycles in eGFR decay and CKD onset; p=0.323 (Table 1 and Figure 1). AKI was very low (1 episode of stage2 (0,7%). New onset anemia was the only significant adverse event observed (p=0.003).
Conclusion
Surprisingly, the pre-operative FLOT regimen seems to have a negligible impact on renal function suggesting the possibility to extend its use even in patient with advanced CKD.
Funding
- Private Foundation Support